For example, National Health Service (NHS) England has made Kymriah (tisagenlecleucel; Novartis, Basel, Switzerland) and Yescarta (axicabtagene ciloleucel; Gilead Sciences, Tokyo, Japan) available ...

At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

Cancer drug company Gritstone Bio Inc. will sell off its pieces to three bidders through U.S. Bankruptcy Court, aiming for a ...

Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.

Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...

Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening for eye disease. The ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...

Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...